Abstracts tagged "gout"

Abstract Number: 332 • 2019 ACR/ARP Annual Meeting
Incident Gout After Renal Transplantation in Gout-naïve Patients: Large Database Analysis
Brian LaMoreaux¹, Megan Francis-Sedlak ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Patients undergoing kidney transplantation are at increased risk for developing hyperuricemia and gout compared to the general population (generally attributed to the frequent use…
Abstract Number: 355 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol
Hanna Zembrzuska¹, Yubo Gao ¹, Saket Girotra ¹, Brian Lund ², Kenneth Saag ³, Jeffrey Curtis ³, Mary Vaughan-Sarrazin ² and Namrata Singh ⁴, ¹University of Iowa Hospitals and Clinics, Iowa City, IA, ²Iowa City VA Health Care System, Iowa City, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Iowa, Iowa City
Background/Purpose: Gout is the most common inflammatory arthritis and is particularly common among veterans. Recent studies, a randomized controlled trial (CARES, White et al. NEJM…
Abstract Number: 1233 • 2019 ACR/ARP Annual Meeting
Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Blanka Stiburkova¹, Yu Toyoda ², Katerina Pavelcova ³, Martin Klein ⁴, Tappei Takada ² and Hiroshi Suzuki ², ¹Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, ²Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, ³Institute of Rheumatology; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
Abstract Number: 2835 • 2019 ACR/ARP Annual Meeting
A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout
Niamh Fanning¹, Ruth Topless ², Christopher Frampton ¹, Murray Cadzow ², Mary Wallace ³, Nicola Dalbeth ⁴, Tony Merriman ⁵ and Lisa Stamp ⁶, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Otago, Otago, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Otago, Birmingham, AL, ⁶University of Otago, Christchurch, Christchurch, Canterbury, New Zealand
Background/Purpose: Current understanding of why the urate lowering effect of allopurinol varies among individuals with gout is limited. The rs2231142 (Q141K) variant of ABCG2 is…
Abstract Number: 333 • 2019 ACR/ARP Annual Meeting
Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients
Justin Li¹, David Yin ¹, Zheng Wang ¹, Mark Brigham ¹, Brian LaMoreaux ², Jeffrey Kent ², Megan Francis-Sedlak ², Richard Johnson ³, Nandini Hadker ¹ and Gavin Miyasato ¹, ¹Trinity Partners, Waltham, MA, ²Horizon Therapeutics plc, Lake Forest, IL, ³University of Colorado Denver, Aurora, CO
Background/Purpose: Although gout has been shown to be associated with poor renal outcomes among chronic kidney disease populations, this relationship is not well understood among…
Abstract Number: 356 • 2019 ACR/ARP Annual Meeting
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Till Uhlig¹, Lars Fridtjof Karoliussen ², Espen A Haavardsholm ², Tore Kvien ¹ and Hilde Hammer ², ¹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ²Diakonhjemmet hospital, Oslo, Norway
Background/Purpose: Urate lowering therapy (ULT) is expected to prevent new gout flares. Treat-to-target ULT is however often not performed, and more evidence on how often…
Abstract Number: 1235 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Wesley DeHaan¹, Alan Kivitz ², Rehan Azeem ¹, Horacio Plotkin ¹, Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Justin Park ¹, Stephen Smolinski ¹ and Sheldon Leung ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long term treatment focuses on reducing sUA…
Abstract Number: 2836 • 2019 ACR/ARP Annual Meeting
Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank
Vicky Tai¹, Ravi Narang ¹, Greg Gamble ¹, Lisa Stamp ², Tony Merriman ³ and Nicola Dalbeth ¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ³University of Otago, Birmingham, AL
Background/Purpose: Both serum urate-associated genetic variants and body mass index (BMI) are associated with gout risk. The aim of this study was to systematically examine…
Abstract Number: 334 • 2019 ACR/ARP Annual Meeting
The Role of a ‘Treat-to-Target’ Approach on Long-term Renal Outcomes in Patients with Gout
Woo-Joong Kim ¹, Jung-Soo Song¹ and Sang Tae Choi ¹, ¹Chung-Ang University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Although gout is accompanied by the substantial burden of kidney disease, there is limited data to assess renal function as a therapeutic target. There…
Abstract Number: 358 • 2019 ACR/ARP Annual Meeting
Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients
Meron Mezgebe¹, Megan Francis-Sedlak ¹, Brian LaMoreaux ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: From 2006 to 2012, gout was the primary indication for ~0.2% of all emergency department visits for adults, as reported in the Nationwide Emergency…
Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
John A. Albert¹, Tony Hosey ² and Brian LaMoreaux ², ¹Rheumatic Disease Center, Milwaukee, IL, ²Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…
Abstract Number: 2839 • 2019 ACR/ARP Annual Meeting
Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts
Nicholas Sumpter¹, Tony Merriman ², Richard Reynolds ³, Abhishek Abhishek ⁴, Mariano Andrés ⁵, Nicola Dalbeth ⁶, Michael Doherty ⁴, Lennart Jacobsson ⁷, Matthijs Janssen ⁸, Tim Jansen ⁹, Leo Joosten ¹⁰, Meliha Kapetanovic ¹¹, Frédéric Lioté ¹², Hirotaka Matsuo ¹³, Geraldine McCarthy ¹⁴, Fernando Perez-Ruiz ¹⁵, Philip Riches ¹⁶, Pascal Richette ¹⁷, Edward Roddy ¹⁸, Blanka Stiburkova ¹⁹, Alex So ²⁰, Lisa Stamp ²¹, Anne-Kathrin Tausche ²², Rosa Torres-Jimenez ²³ and Till Uhlig ²⁴, ¹University of Otago, Birmingham, ²University of Otago, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Nottingham, Nottingham, United Kingdom, ⁵Hospital General Universitario de Alicante, Alicante, Spain, ⁶University of Auckland, Auckland, New Zealand, ⁷Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁸Rijnstate Hospital, Arnhem, Netherlands, ⁹Viecuri MC, Venlo, Netherlands, ¹⁰Department of Internal Medicine and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands, ¹¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ¹²Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, ¹³National Defense Medical College, Tokorozawa, Japan, ¹⁴University College Dublin, Dublin, Ireland, ¹⁵Hospital de Cruces, Vizcaya, Spain, ¹⁶The University of Edinburgh, Edinburgh, United Kingdom, ¹⁷Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ¹⁸Research Institute for Primary Care and Health Sciences and Keele Clinical Trials Unit, Keele, United Kingdom, ¹⁹Institute of Rheumatology; Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic, ²⁰Universite de Lausanne, Lausanne, Switzerland, ²¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²²Universitatsklinikum Dresden, Dresden, Germany, ²³Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Spain, ²⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway
Background/Purpose: This study aimed to determine whether a polygenic risk score (PRS) based on gout-associated genetic variants is associated with gout disease severity phenotypes such…
Abstract Number: 335 • 2019 ACR/ARP Annual Meeting
Renal Transplant Complications in Patients with and Without Gout
Megan Francis-Sedlak¹, Brian LaMoreaux ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Graft-related complications are among the most serious issues solid-organ transplant recipients and their healthcare teams face post-operatively. Gout is a known frequent co-morbidity in…
Abstract Number: 360 • 2019 ACR/ARP Annual Meeting
Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis
Philip Robinson¹, Nicola Dalbeth ² and Peter Donovan ³, ¹University of Queensland, Brisbane, Queensland, Australia, ²University of Auckland, Auckland, New Zealand, ³University of Queensland, HERSTON, Australia
Background/Purpose: Prophylaxis of acute gout flares when commencing urate lowering therapy is recommended by international guidelines. Whether this is a cost-effective intervention is currently unknown.…
Abstract Number: 1238 • 2019 ACR/ARP Annual Meeting
Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Félix Renaudin ¹, Laure Campillo-Gimenez ², Florence Castelli ³, François Fenaille ³, Aurélie Prignon ⁴, Christele Combes ⁵, Martine Cohen-Solal ¹, Frédéric Lioté ⁶ and Hang Korng Ea¹, ¹Université Paris, INSERM UMR1132 BIOSCAR, Paris, France, ²Université Paris, INSERM UMR1132 BIOSCAR, San Diego, ³CEA Paris-Saclay, Laboratoire d’Etudes du Métabolisme des Médicaments, Saclay, France, ⁴UMS28 Phénotypage du petit animal, Laboratoire d'Imagerie Moléculaire Positonique (LIMP), Sorbonne Univerity, Paris, France, ⁵CIRIMAT, Université de Toulouse, INPT,UPS,CNRS,ENSIACET, Toulouse, France, ⁶Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France
Background/Purpose: Monosodium urate (MSU) andmonoclinic calcium pyrophosphate dihydrated(mCPPD)crystals are responsible for relapsing acute arthritis which is driven by interleukin 1β (IL-1β).IL-1βproductionrelies onNLRP3 inflammasome activationleading to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].